Clinical Trials Browser

Phase 4 × INDUSTRY × lorlatinib × Clear all

NCT05144997 2025-12-17

Lorlatinib Continuation Study

Phase 4 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04362072 2025-06-11

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

Phase 4 Completed

71 enrolled 26 charts

Carcinoma

NCT04541706 2024-12-20

Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

Phase 4 Completed

100 enrolled 10 charts

Advanced Non-Small Cell Lung Cancer